Two Sigma Advisers’s Ocular Therapeutix OCUL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-73,100
| Closed | -$536K | – | 2469 |
|
|
2025
Q1 | $536K | Buy |
73,100
+36,400
| +99% | +$267K | ﹤0.01% | 1745 |
|
|
2024
Q4 | $313K | Buy |
36,700
+26,300
| +253% | +$225K | ﹤0.01% | 1962 |
|
|
2024
Q3 | $90.5K | Sell |
10,400
-26,900
| -72% | -$234K | ﹤0.01% | 2176 |
|
|
2024
Q2 | $255K | Buy |
+37,300
| New | +$255K | ﹤0.01% | 2134 |
|
|
2023
Q4 | – | Sell |
-33,700
| Closed | -$106K | – | 2603 |
|
|
2023
Q3 | $106K | Sell |
33,700
-320,500
| -90% | -$1.01M | ﹤0.01% | 2202 |
|
|
2023
Q2 | $1.83M | Buy |
354,200
+44,800
| +14% | +$231K | ﹤0.01% | 1253 |
|
|
2023
Q1 | $1.63M | Sell |
309,400
-12,300
| -4% | -$64.8K | ﹤0.01% | 1379 |
|
|
2022
Q4 | $904K | Sell |
321,700
-34,500
| -10% | -$96.9K | ﹤0.01% | 1618 |
|
|
2022
Q3 | $1.48M | Sell |
356,200
-32,900
| -8% | -$137K | ﹤0.01% | 1333 |
|
|
2022
Q2 | $1.56M | Sell |
389,100
-296,000
| -43% | -$1.19M | ﹤0.01% | 1344 |
|
|
2022
Q1 | $3.39M | Sell |
685,100
-105,700
| -13% | -$523K | 0.01% | 982 |
|
|
2021
Q4 | $5.51M | Sell |
790,800
-285,500
| -27% | -$1.99M | 0.01% | 726 |
|
|
2021
Q3 | $10.8M | Sell |
1,076,300
-110,800
| -9% | -$1.11M | 0.03% | 491 |
|
|
2021
Q2 | $16.8M | Sell |
1,187,100
-35,200
| -3% | -$499K | 0.04% | 380 |
|
|
2021
Q1 | $20.1M | Buy |
1,222,300
+157,200
| +15% | +$2.58M | 0.06% | 361 |
|
|
2020
Q4 | $22M | Buy |
1,065,100
+740,100
| +228% | +$15.3M | 0.06% | 326 |
|
|
2020
Q3 | $2.47M | Buy |
325,000
+291,100
| +859% | +$2.22M | 0.01% | 1055 |
|
|
2020
Q2 | $282K | Buy |
+33,900
| New | +$282K | ﹤0.01% | 2142 |
|